Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TCF3
REST API REST API
Homo sapiens
TCF3 is differentially expressed in 413 experiments: 174 organism parts: bone marrow, ovary, ... (172 more);, 305 disease states: normal, control, ... (303 more);, 128 cell types 563 cell lines 61 compound treatments and 93 other conditions.
Synonyms ITF1, VDIR, MGC129648, MGC129647, E2A, bHLHb21, E47
Orthologs tcf3 (Danio rerio)   TCF3 (Bos taurus)   Q788W0_CHICK (Gallus gallus)   Tcf3 (Rattus norvegicus)   Tcf3 (Mus musculus)   TCF3 (1 of 2) (Danio rerio)   tcf3 (Xenopus laevis)   TCF3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein stabilization, protein binding, regulation of transcription, DNA-dependent, cytoplasm, protein complex, transcription, DNA-dependent, positive regulation of gene expression, nuclear nucleosome, G1 phase of mitotic cell cycle, transcription factor binding, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, transcription coactivator activity, nucleus, muscle cell differentiation, protein heterodimerization activity, response to lipopolysaccharide, transcription factor complex, histone H3 acetylation, positive regulation of cell cycle, response to drug, nervous system development, chromatin binding, protein homodimerization activity, nucleoplasm, regulation of transcription from RNA polymerase II promoter, bHLH transcription factor binding, positive regulation of transcription, DNA-dependent, B cell differentiation, positive regulation of B cell proliferation, Peyer's patch development, positive regulation of neuron differentiation, vitamin D response element binding, immunoglobulin V(D)J recombination, E-box binding, natural killer cell differentiation, lymphocyte differentiation, positive regulation of muscle cell differentiation, mitogen-activated protein kinase kinase kinase binding, B cell lineage commitment, cell development, histone H4 acetylation, sequence-specific DNA binding transcription factor activity, T cell differentiation in thymus, transcription regulatory region DNA binding, repressing transcription factor binding, positive regulation of sequence-specific DNA binding transcription factor activity
InterPro Term HLH_DNA-bd
UniProt Accession Q2TB39, B1NYC3, Q6PJU3, P15923, F5GZ25
Search EB-eye ENSG00000071564
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-MEXP-433, E-GEOD-7540, ... (35 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, ... (52 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529, E-GEOD-5823
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MCF-10A
2
E-TABM-420, E-GEOD-14990
557 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-120, E-MEXP-750, ... (66 experiments)

Factor Value U/D Experiments
CD4+ T cell
2
4
E-GEOD-16190, E-MTAB-24, E-GEOD-6740, E-MTAB-25, E-AFMX-5, ... (6 experiments)
CD8+ T cell
2
E-GEOD-6740, E-AFMX-5
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
centroblast
2
E-TABM-702, E-GEOD-15271
mononuclear
2
E-GEOD-13987, E-GEOD-26672
122 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (93 experiments)

Factor Value U/D Experiments
control
1
5
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363, E-GEOD-20295, E-GEOD-16728, ... (6 experiments)
colon carcinoma
4
E-MTAB-37, E-GEOD-3726, E-MTAB-62, E-MTAB-57
cervical carcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-5823
dermatomyositis
3
E-MTAB-62, E-GEOD-5370, E-GEOD-1551
prostate carcinoma
3
E-GEOD-96, E-MEXP-1327, E-MEXP-2034
lung adenocarcinoma
1
3
E-MTAB-37, E-MTAB-62, E-MEXP-231, E-GEOD-2514
299 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, ... (41 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
dimethyl sulfoxide
2
E-GEOD-5824, E-GEOD-6932
control
1
2
E-GEOD-995, E-GEOD-3284, E-GEOD-4006
M-CSF
1
E-GEOD-5099
mercaptopurine, methotrexate
1
E-GEOD-412
oligomycin
1
E-MEXP-2285
55 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
1
E-GEOD-21521
not specified
1
1
E-GEOD-21521
GTE6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-MEXP-1251, E-GEOD-4619, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, ... (11 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22541, ... (11 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-6207, E-GEOD-7011, E-MTAB-73, E-GEOD-7578, ... (13 experiments)

Genotype
studied in E-TABM-763, E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-GEOD-18736, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-GEOD-10315, E-TABM-440, E-GEOD-837, E-MEXP-1273, ... (17 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20559, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-GEOD-974, E-MEXP-1956, ... (46 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (8 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-MEXP-2177

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-22541, E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-5824, E-GEOD-1460, E-GEOD-17636, ... (13 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-22541, E-GEOD-7540, E-GEOD-7307 ... (5 experiments)

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.484 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM